Dentsply Sirona faces mounting pressure as declining sales and poor capital returns challenge its recovery narrative. With shares down sharply over multiple years, investors question management's strategy in a competitive dental market.
A devastating landslide at the Rubaya coltan mine in eastern DRC has claimed hundreds of lives, casting a harsh spotlight on the perilous conditions in artisanal mining and the complex conflict over the region's critical minerals.
While famously dismissing gold as a non-productive asset, Warren Buffett's historic silver investment reveals a preference for metals with tangible industrial utility—a distinction growing more relevant as silver deficits deepen amid soaring green-energy demand.
Amid soaring valuations and bubble fears, venture capital heavyweight Ben Horowitz argues the AI surge is fundamentally different, driven by historic customer adoption and revenue growth that signals a new computing era.
A recent discounted cash flow analysis suggests D&O Green Technologies Berhad's stock may be significantly undervalued, trading around RM0.60 against a calculated fair value of RM0.89. The semiconductor-focused firm's current valuation presents a notable gap for investors to consider.
As tech volatility reshuffles investor priorities in early 2026, a screen for strength and analyst conviction highlights three dividend payers—from lithium to offshore drilling—that are already setting the pace.
As earnings season unfolds, Apple and Meta Platforms both posted impressive results, but their paths diverge sharply. Apple's growth reaccelerates on iPhone strength, while Meta's robust outlook is shadowed by soaring AI investments. The debate over which stock offers the better value is heating up.
China's factory activity unexpectedly contracted in January, official data shows, reversing a brief December expansion and underscoring persistent domestic demand challenges despite robust exports.
Despite an 11.8% rally in 2026, BigBear.ai faces a pivotal shareholder vote that could dictate its acquisition-fueled growth strategy and test investor confidence.
The unraveling of the R&R Family of Companies is sending shockwaves through the freight industry, with a new lawsuit from Vantage Carrier alleging over $1.3 million in unpaid invoices. The case adds to a growing pile of legal claims and exposes the precarious financial exposure of carriers and small operators caught in the wake.
Gulfport Energy (NYSE: GPOR) shares have surged roughly 200% over three years, yet a deep dive reveals conflicting signals. While a cash flow model suggests significant undervaluation, its price-to-sales ratio tells a more cautious tale, leaving investors to weigh the metrics against a volatile energy backdrop.
SoundHound AI expands its real-world footprint with a nationwide rollout of voice AI at Five Guys and partners with Bridgepointe Technologies to target the enterprise market, signaling a dual-path growth strategy.
Galderma Group's (SWX:GALD) shares have faced significant pressure in recent months, contrasting sharply with its strong yearly performance. This analysis delves into whether the current valuation presents a genuine entry point or reflects deeper concerns about the dermatology giant's ambitious growth narrative.
Facing a significant stock decline and a challenging Medicare Advantage outlook, UnitedHealth Group announces leadership changes and a 'Back to Basics' operational reset, aiming to stabilize its core business amid shifting market dynamics.
RH shares have cratered over 50% in the past year, battered by concerns over high-end consumer spending. While a key valuation model suggests the luxury home furnishing retailer is deeply undervalued, its premium earnings multiple tells a conflicting story, leaving investors to question if this is a buying opportunity or a sign of deeper troubles.
Barrick Gold (TSX:ABX) has delivered staggering returns of over 150% in five years, leaving investors to question if the rally has run its course. A deep dive into valuation models suggests the stock may still be trading at a significant discount to its intrinsic value.
In a major strategic shift, uranium-focused Energy Fuels announces a deal to acquire Australian Strategic Materials, aiming to create a vertically integrated rare earths producer outside China. The move comes as the company's stock, already on a meteoric rise, faces new questions about its growth trajectory and valuation.
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
An analysis of Mooreast Holdings' financial metrics reveals a worrying trend of declining returns on capital employed, despite growth in its asset base. The company's performance lags behind its own historical figures, prompting a closer look from the market.
